Wanbury Limited (WANBURY) - Net Assets

Latest as of September 2025: Rs1.07 Billion INR ≈ $11.60 Million USD

Based on the latest financial reports, Wanbury Limited (WANBURY) has net assets worth Rs1.07 Billion INR (≈ $11.60 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.57 Billion ≈ $49.38 Million USD) and total liabilities (Rs3.49 Billion ≈ $37.78 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Wanbury Limited (WANBURY) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets Rs1.07 Billion
% of Total Assets 23.49%
Annual Growth Rate -2.77%
5-Year Change N/A
10-Year Change N/A
Growth Volatility 69.93

Wanbury Limited - Net Assets Trend (2006–2025)

This chart illustrates how Wanbury Limited's net assets have evolved over time, based on quarterly financial data. Also explore WANBURY current and non-current assets for the complete picture of this company's asset base.

Annual Net Assets for Wanbury Limited (2006–2025)

The table below shows the annual net assets of Wanbury Limited from 2006 to 2025. For live valuation and market cap data, see WANBURY market cap.

Year Net Assets Change
2025-03-31 Rs592.72 Million
≈ $6.41 Million
+112.13%
2024-03-31 Rs279.41 Million
≈ $3.02 Million
+185.15%
2023-03-31 Rs-328.16 Million
≈ $-3.55 Million
-40.12%
2022-03-31 Rs-234.20 Million
≈ $-2.53 Million
+85.01%
2021-03-31 Rs-1.56 Billion
≈ $-16.90 Million
-8.92%
2020-03-31 Rs-1.43 Billion
≈ $-15.51 Million
+31.45%
2019-03-31 Rs-2.09 Billion
≈ $-22.63 Million
-13.32%
2018-03-31 Rs-1.85 Billion
≈ $-19.97 Million
-20.49%
2017-03-31 Rs-1.53 Billion
≈ $-16.58 Million
+6.10%
2016-03-31 Rs-1.63 Billion
≈ $-17.65 Million
+7.88%
2015-03-31 Rs-1.77 Billion
≈ $-19.16 Million
-7.35%
2014-03-31 Rs-1.65 Billion
≈ $-17.85 Million
-675.06%
2013-03-31 Rs-212.95 Million
≈ $-2.30 Million
-129.95%
2012-03-31 Rs711.13 Million
≈ $7.69 Million
-32.26%
2011-03-31 Rs1.05 Billion
≈ $11.35 Million
-45.45%
2010-03-31 Rs1.92 Billion
≈ $20.81 Million
+21.46%
2009-03-31 Rs1.58 Billion
≈ $17.13 Million
+22.71%
2007-03-31 Rs1.29 Billion
≈ $13.96 Million
+27.66%
2006-03-31 Rs1.01 Billion
≈ $10.94 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Wanbury Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 108352500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2025)

Component Amount Percentage
Common Stock Rs327.70 Million 55.29%
Other Components Rs1.35 Billion 227.52%
Total Equity Rs592.72 Million 100.00%

Wanbury Limited Competitors by Market Cap

The table below lists competitors of Wanbury Limited ranked by their market capitalization.

Company Market Cap
Bridgemarq Real Estate Services Inc
TO:BRE
$96.12 Million
Prozone Realty Limited
NSE:PROZONER
$96.17 Million
CAIRO MEZZ PLC EO-10
F:6H3
$96.17 Million
Adverum Biotechnologies Inc
NASDAQ:ADVM
$96.26 Million
Media Prima Bhd
KLSE:4502
$96.08 Million
Petrochemical
TA:PTCH
$96.06 Million
BioPorto
CO:BIOPOR
$96.05 Million
ALT5 Sigma Corporation
NASDAQ:ALTS
$96.02 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Wanbury Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 279,414,000 to 592,718,000, a change of 313,304,000 (112.1%).
  • Net income of 305,301,000 contributed positively to equity growth.
  • Share repurchases of 250,000 reduced equity.
  • New share issuances of 250,000 increased equity.
  • Other comprehensive income decreased equity by 179,638,000.
  • Other factors increased equity by 187,641,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income Rs305.30 Million +51.51%
Share Repurchases Rs250.00K -0.04%
Share Issuances Rs250.00K +0.04%
Other Comprehensive Income Rs-179.64 Million -30.31%
Other Changes Rs187.64 Million +31.66%
Total Change Rs- 112.13%

Book Value vs Market Value Analysis

This analysis compares Wanbury Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 14.59x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 2.79x to 14.59x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-03-31 Rs91.16 Rs254.28 x
2007-03-31 Rs97.01 Rs254.28 x
2009-03-31 Rs102.66 Rs254.28 x
2010-03-31 Rs125.81 Rs254.28 x
2011-03-31 Rs84.22 Rs254.28 x
2012-03-31 Rs30.23 Rs254.28 x
2013-03-31 Rs-27.59 Rs254.28 x
2015-03-31 Rs-97.12 Rs254.28 x
2016-03-31 Rs-94.53 Rs254.28 x
2017-03-31 Rs-73.66 Rs254.28 x
2018-03-31 Rs-77.86 Rs254.28 x
2019-03-31 Rs-88.23 Rs254.28 x
2020-03-31 Rs-59.86 Rs254.28 x
2021-03-31 Rs-62.48 Rs254.28 x
2022-03-31 Rs-7.25 Rs254.28 x
2023-03-31 Rs-1.88 Rs254.28 x
2024-03-31 Rs8.44 Rs254.28 x
2025-03-31 Rs17.43 Rs254.28 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Wanbury Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 51.51%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.09%
  • • Asset Turnover: 1.45x
  • • Equity Multiplier: 6.98x
  • Recent ROE (51.51%) is above the historical average (5.61%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 10.61% 9.86% 0.56x 1.93x Rs6.16 Million
2007 16.13% 14.48% 0.45x 2.48x Rs79.14 Million
2009 -21.31% -13.23% 0.29x 5.53x Rs-472.21 Million
2010 4.55% 1.78% 0.59x 4.36x Rs-100.66 Million
2011 -67.73% -21.63% 0.51x 6.15x Rs-961.58 Million
2012 -87.50% -10.07% 0.48x 18.24x Rs-433.39 Million
2013 0.00% -19.00% 0.59x 0.00x Rs-824.34 Million
2014 0.00% -19.30% 1.09x 0.00x Rs-659.68 Million
2015 0.00% 1.28% 0.63x 0.00x Rs225.98 Million
2016 0.00% -1.69% 1.11x 0.00x Rs117.30 Million
2017 0.00% 14.45% 1.04x 0.00x Rs773.43 Million
2018 0.00% -8.70% 1.35x 0.00x Rs-135.40 Million
2019 0.00% -6.42% 1.35x 0.00x Rs-39.20 Million
2020 0.00% 17.78% 1.30x 0.00x Rs788.07 Million
2021 0.00% -3.26% 1.34x 0.00x Rs30.19 Million
2022 0.00% 15.94% 1.45x 0.00x Rs838.16 Million
2023 0.00% -2.09% 1.64x 0.00x Rs-97.80 Million
2024 200.26% 9.74% 1.67x 12.29x Rs531.62 Million
2025 51.51% 5.09% 1.45x 6.98x Rs246.03 Million

Industry Comparison

This section compares Wanbury Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $23,713,303,062
  • Average return on equity (ROE) among peers: 8.81%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Wanbury Limited (WANBURY) Rs1.07 Billion 10.61% 3.26x $96.08 Million
Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) $988.60 Million 6.59% 1.36x $27.93 Million
Aarti Drugs Limited (AARTIDRUGS) $6.52 Billion 21.67% 1.42x $371.43 Million
Aarti Pharmalabs Limited (AARTIPHARM) $19.90 Billion 13.69% 0.46x $725.68 Million
Abbott India Limited (ABBOTINDIA) $36.99 Billion 32.48% 0.40x $5.85 Billion
Ajanta Pharma Limited (AJANTPHARM) $1.16 Billion 12.69% 1.32x $3.81 Billion
Akums Drugs and Pharmaceutical (AKUMS) $6.25 Billion -40.39% 3.91x $906.19 Million
Alkem Laboratories Limited (ALKEM) $88.47 Billion 18.60% 0.59x $6.98 Billion
Amrutanjan Health Care Limited (AMRUTANJAN) $1.46 Billion 16.82% 0.29x $178.52 Million
Alembic Pharmaceuticals Limited (APLLTD) $51.90 Billion 11.24% 0.50x $1.60 Billion
Aurobindo Pharma Limited (AUROPHARMA) $23.50 Billion -5.26% 1.65x $8.73 Billion

About Wanbury Limited

NSE:WANBURY India Drug Manufacturers - Specialty & Generic
Market Cap
$96.08 Million
Rs8.88 Billion INR
Market Cap Rank
#19327 Global
#1035 in India
Share Price
Rs254.28
Change (1 day)
-1.43%
52-Week Range
Rs163.34 - Rs312.65
All Time High
Rs321.85
About

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more